WALTHAM, Mass., Sept. 12, 2019 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today issued the following letter, which will be mailed to its shareholders.
AMAG’s Board urges all AMAG shareholders to refrain from taking any action (including returning any consent card sent by Caligan) at this time. The Company’s Board of Directors, in consultation with its advisors, is reviewing Caligan’s solicitation materials and will advise AMAG’s shareholders of its recommendation regarding Caligan’s solicitation in due course.
*** SHAREHOLDERS SHOULD TAKE NO ACTION ON CALIGAN’S CONSENT SOLICITATION ***
September 12, 2019
Dear AMAG Shareholder:
You may soon receive consent solicitation materials from Caligan Partners LP, a hedge fund that accumulated its entire stake in AMAG Pharmaceuticals, Inc. within the past three months. Caligan has indicated that it intends to seek your written consent to remove and replace four members of your AMAG Board of Directors. Additionally, the Company is carefully reviewing the proposed ideas from Caligan, as it is concerned that certain actions pushed by Caligan may be destructive to the long-term value of the Company.
The Board is committed to acting in the best interest of shareholders and maximizing long-term value creation, and remains steadfast in its belief that any corporate action taken must be for the benefit of all AMAG shareholders. Since 2017, the Company has made significant progress executing on its ambitious five-year strategic plan to develop and commercialize innovative products. In this timeframe, AMAG has successfully transformed from a specialty pharmaceuticals company with only two assets into a pharmaceutical company with four commercial therapies and two development-stage programs all while strengthening the financial profile of the Company. AMAG has streamlined and diversified its product portfolio and development pipeline through the divestiture of the CBR business and the acquisitions of AMAG-423 and ciraparantag and significantly strengthened its balance sheet through debt reduction and salesforce consolidation. Your Board believes that the removal of four highly-qualified and experienced members of the Board would be detrimental to the Company and our shareholders.
*** WE STRONGLY URGE YOU TO WAIT FOR AMAG’s CONSENT REVOCATION STATEMENT AND
GREEN CONSENT REVOCATION CARD FORM ***
It is imperative that shareholders take the necessary time to review relevant information, including the recommendation of AMAG’s Board, before taking any action with respect to Caligan’s consent solicitation. The Company intends to mail to you a consent revocation statement and accompanying GREEN consent revocation card, which will explain in more detail the Board’s reasons for opposing Caligan’s consent solicitation.
***DO NOT SIGN ANY WHITE CALIGAN CONSENT***
We urge all shareholders to refrain from taking any action at this time and to WAIT for AMAG’s consent revocation statement and GREEN consent revocation card. In the meantime, we urge all shareholders to disregard Caligan’s consent efforts and discard any materials that may have been sent to you by Caligan. If you have any questions or require assistance, please contact AMAG’s proxy solicitor, Innisfree M&A Incorporated, by calling toll-free at (877) 750-0926 or collect at (212) 750-5833.
Sincerely,
| Gino Santini | William K. Heiden |
| Chairman of the Board | President and Chief Executive Officer |
About AMAG
AMAG is a pharmaceutical company focused on bringing innovative products to patients with unmet medical needs. The company does this by leveraging its development and commercial expertise to invest in and grow its pharmaceutical products across a range of therapeutic areas, including women’s health. For additional company information, please visit www.amagpharma.com.

